Research progress on dose-effect-toxicity relationship of EGFR- and ALK-tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
10.3760/cma.j.cn114015-20231129-00845
- VernacularTitle:EGFR和ALK酪氨酸激酶抑制剂治疗非小细胞肺癌的量-效-毒关系研究进展
- Author:
Yihan PEI
1
;
Yue LI
1
;
Yunyan BI
1
;
Nan GUO
1
;
Wen ZHANG
1
Author Information
1. 山东第一医科大学附属省立医院药学部，济南 250021
- Publication Type:Journal Article
- Keywords:
Molecular targeted therapy;
Dose-response relationship, drug;
Receptor, epidermal growth factor;
Anaplastic lymphoma kinase;
Tyrosine kinase inhibitors;
Ad
- From:
Adverse Drug Reactions Journal
2024;26(3):178-183
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy is one of the important methods of treatment for non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have the characteristics of high efficacy and low toxicity, and are used in the precise treatment in NSCLC patients with gene mutation. Common gene mutations include genes encoding epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Different patients have different responses to TKIs. Monitoring the blood concentration of TKIs can help better predict the clinical outcome (efficacy/toxicity) and optimize the treat strategies. In this paper, the relevant literature at home and abroad in the past 10 years are searched, and the relationship between the blood trough concentration of EGFR-TKI and ALK-TKI commonly used in clinic and the efficacy/toxicity are reviewed.
